Dr. Ravi Braich has a chemistry background and is counsel in the Patent practice group. He focuses his practice on U.S. and foreign patent prosecution, opinion work, and counseling clients in the areas of chemical, diagnostics, therapeutics, pharmaceutical, biotechnology, and life sciences.
I focus my practice on helping clients, including hospitals, research institutes and small and medium size companies, devise and pursue effective strategies for protecting their breakthrough technologies. I have experience in a wide range of technologies including small molecules, nucleic acid based technologies (RNAi, activating RNAs, antisense nucleic acids and microRNAs), peptides, antibodies, prodrugs and drug conjugates, anesthetics, diagnostic/imaging agents, antiviral agents, cancer vaccines, semi-conductor materials, drug targeting and drug delivery, microfluidic devices, drug delivery devices, diagnostic devices and biomimetic devices. This work involves their synthesis, purification, and use.
I focus on strategic patent counseling and prosecution in areas of chemical, diagnostics, therapeutics and pharmaceuticals in all phases of development, within and outside the United States.
I work closely with corporations, universities and licensee counsel on strategic management and growth of their patent portfolios.
I work with clients in varieties of industries to conduct patentability and freedom to operate analysis, and competitive intelligence and analysis in areas of small molecules, nucleic acids, polymers and diagnostic methods and devices.
I believe that more patent owners, not just pharmaceutical companies, will look to create sovereign immunity claims for fending of inter partes review (IPR) before the Patent Trial and Appeal Board.
Bloomberg Law | February 17, 2021
This roundup of notable legal industry news and people moves includes Nixon Peabody’s promotion of 12 attorneys to counsel.
Intellectual Property & Technology Law Journal | May 01, 2020
Intellectual Property partner Pete Prommer in Chicago and associate Ravi Braich, Ph.D. in Boston contributed this article analyzing the Supreme Court’s denial of several petitions for certiorari on patent decision in HP Inc. v. Berkheimer, and the effect on patent owners and applicants. Click here for the full article.
Intellectual Property & Technology Law Journal | December 05, 2019
Intellectual Property associates Sydney Pritchett, Ben Rosborough and Ravi Braich authored this patent alert about remaining questions and uncertainty following the U.S. Supreme Court ‘s ruling in Helsinn Healthcare S.A. v. Teva Pharmaceuticals U.S.
Intellectual Property Alert | 04.29.20
Intellectual Property Alert | 03.24.20
Intellectual Property Alert | 01.27.20
Intellectual Property Alert | 12.16.19
Intellectual Property Alert | 12.06.19
Intellectual Property Alert | 09.06.19